The stagflation specter is spooking traders today, wiping out the risk-on move that was buoying stocks and weighing on board ...

Bristol Myers Squibb has released new 5-year results from the long-term trial evaluating Sotyktu for the treatment of adults ...

Highlights,Bristol-Myers Squibb remains focused on pharmaceutical innovation and strategic developments.,The company ...

Corvus Pharmaceuticals' Soquelitinib shows promise for PTCL & more, but financial risks and competition raise concerns. Learn more about CRVS stock here.

DelveInsight’s, “Gastric Cancer Pipeline Insight” report provides comprehensive insights about 200+ companies and 220+ ...

As Bristol Myers Squibb rolls ahead with its plan to cut $1.5 billion in costs by the end of the year, the drugmaker is once ...

Quintet Private Bank Europe S.A. reduced its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 8.8% in ...

Shares of Bristol Myers Squibb Co. BMY rose 1.39% to $59.62 Friday, on what proved to be an all-around positive trading ...

Along with Nutley-based Eisai, several other New Jersey-based giants in the space have conducted layoffs over the past few ...

The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly ...

Plaintiffs lawyers seem to steer personal injury cases to the Philadelphia Common Pleas Court, and corporate defendants ...

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...